CA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

CA Cancer J Clin 2001; 51:329
doi: 10.3322/canjclin.51.6.329
© 2001 American Cancer Society
This Article
Right arrow Full Text Freely available
Right arrow Full Text (PDF) Freely available
Right arrow Freely available CME: Take the course for this article:
 Comorbidity Considerations in Geriatric Oncology Research
Right arrow Submit a letter to the editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yates, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yates, J. W.

Comorbidity Considerations in Geriatric Oncology Research

Jerome W. Yates, MD, MPH

Dr. Yates is Senior Vice President, Population Sciences and Health Services Research, Roswell Park Cancer Institute, and Professor of Medicine, State University of New York at Buffalo, Buffalo, NY.

Although it is generally acknowledged that comorbidity has a significant impact on treatment selection and outcomes for elderly patients with cancer, an understanding of how comorbid conditions should influence clinical decisions is quite incomplete. This issue remains an important and challenging area of geriatric oncology research. Measures of comorbidity require recognition, documentation, and accurate data extraction. Extensive prospective evaluations and medical chart reviews have the greatest reliability but are costly. Administrative data are convenient and applicable to large populations, but suffer from relatively poor reliability and therefore should be used with caution. Perhaps in the future more refined nosology and better information systems will improve our understanding and ability to use administrative data sets to study comorbidity in the elderly—the eventual goal of such investigation being evidence-based criteria for care of elderly cancer patients.




This article has been cited by other articles:


Home page
 J Aging HealthHome page
S. L. McFall and M. Davila
Gender, Social Ties, and Cancer Screening Among Elderly Persons
J Aging Health, December 1, 2008; 20(8): 997 - 1011.
[Abstract] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
A. Sanabria, A. L. Carvalho, J. G. Vartanian, J. Magrin, M. K. Ikeda, and L. P. Kowalski
Validation of the Washington University Head and Neck Comorbidity Index in a Cohort of Older Patients
Arch Otolaryngol Head Neck Surg, June 1, 2008; 134(6): 603 - 607.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
A. Sanabria, A. L. Carvalho, J. G. Vartanian, J. Magrin, M. K. Ikeda, and L. P. Kowalski
Comorbidity Is a Prognostic Factor in Elderly Patients with Head and Neck Cancer
Ann. Surg. Oncol., April 1, 2007; 14(4): 1449 - 1457.
[Abstract] [Full Text] [PDF]

Home page
 Arch Pediatr Adolesc MedHome page
D. Tai, P. Dick, T. To, and J. G. Wright
Development of Pediatric Comorbidity Prediction Model
Arch Pediatr Adolesc Med, March 1, 2006; 160(3): 293 - 299.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
J. F. Piccirillo, R. M. Tierney, I. Costas, L. Grove, and E. L. Spitznagel Jr
Prognostic Importance of Comorbidity in a Hospital-Based Cancer Registry
JAMA, May 26, 2004; 291(20): 2441 - 2447.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
J. M. Bennett
Cancer and Aging: Why Not Waltz Together?
CA Cancer J Clin, November 1, 2001; 51(6): 327 - 328.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by American Cancer Society.